Humedix Co (200670) Fair Value & Analysis
Healthcare · KR · Market cap 295B KRW
Fair value as of: Jun 25, 2026
Analysis
Humedix Co (200670) currently trades at 27,400 KRW, while our model-based Fair Value estimate is 70,485 KRW — implying the stock looks roughly 157.2% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
About the company
Humedix Co., Ltd. engages in the manufacture and sale of various pharmaceutical products in South Korea. The company offers prescription medicines, active pharmaceutical ingredients, medical devices, cosmetics, and health functional food products. It is also involved in the manufacture and distribution of anticancer drugs. The company was formerly known as HVLS Co., Ltd. and changed its name to Humedix Co., Ltd. in 2010. Humedix Co., Ltd. was founded in 2002 and is headquartered in Seongnam-si, South Korea.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Humedix Co (200670) undervalued?
What is the fair value of 200670?
What is the quality score of 200670?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.